Skip to main content
رجوع
KNSA logo

Kiniksa Pharmaceuticals, Ltd.

جودة البيانات: 100%
KNSA
NASDAQ Healthcare Biotechnology
KWD 46.04
▼ KWD 0.04 (-0.09%)
القيمة السوقية: 3.42B
نطاق اليوم
KWD 45.71 KWD 47.17
نطاق 52 أسبوعًا
KWD 18.26 KWD 49.12
حجم التداول
623,032
متوسط 50 يوم / 200 يوم
KWD 44.22 / KWD 37.72
الإغلاق السابق
KWD 46.08

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 57.9 0.4
P/B 6.0 2.9
ROE % 11.7 3.7
Net Margin % 8.7 3.8
Rev Growth 5Y % 104.8 10.0
D/E 0.0 0.2

النقاط الرئيسية

Revenue grew 104.76% annually over 5 years — strong growth
ROE of 11.73% — decent returns on equity
Debt/Equity of 0.02 — conservative balance sheet
Generating 25.41M in free cash flow
P/E of 57.90 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 44.67%

النمو

Revenue Growth (5Y)
104.76%
Revenue (1Y)60.09%
Earnings (1Y)N/A
FCF Growth (3Y)38.90%

الجودة

Return on Equity
11.73%
ROIC10.04%
Net Margin8.71%
Op. Margin11.40%

الأمان

Debt / Equity
0.02
Current Ratio3.79
Interest Coverage0.00

التقييم

P/E Ratio
57.90
P/B Ratio6.02
EV/EBITDA42.22
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 60.09% Revenue Growth (3Y) 58.34%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 104.68%
Revenue Growth (5Y) 104.76% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 677.56M Net Income (TTM) 59.01M
ROE 11.73% ROA 7.73%
Gross Margin 54.63% Operating Margin 11.40%
Net Margin 8.71% Free Cash Flow (TTM) 25.41M
ROIC 10.04% FCF Growth (3Y) 38.90%
Safety
Debt / Equity 0.02 Current Ratio 3.79
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 57.90 P/B Ratio 6.02
P/S Ratio 5.04 PEG Ratio -0.22
EV/EBITDA 42.22 Dividend Yield 0.00%
Market Cap 3.42B Enterprise Value 3.26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 677.56M 423.24M 270.26M 220.18M 38.54M
Net Income 59.01M -43.19M 14.08M 183.36M -157.92M
EPS (Diluted) 0.75 -0.60 0.20 2.60 -2.30
Gross Profit 370.15M 362.33M 213.74M 197.29M 29.44M
Operating Income 77.22M -45.62M -25.20M 9.77M -156.64M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 763.63M 580.55M 526.32M 459.67M 232.80M
Total Liabilities 196.03M 142.12M 87.48M 63.52M 47.76M
Shareholders' Equity 567.61M 438.44M 438.84M 396.15M 185.04M
Total Debt 9.50M 9.86M 12.26M 5.92M 6.05M
Cash & Equivalents 165.60M 183.58M 107.95M 122.72M 122.47M
Current Assets 527.18M 331.80M 276.30M 243.06M 196.45M
Current Liabilities 139.18M 100.62M 63.67M 47.07M 44.82M